

Pipeline

	Asset	Indication	Preclinical	Phase 1	Phase 2	Phase 3	Rights
Oncology							
Off-the-shelf	VB10.16	HPV16+ cervical cancer					1
	VB10.16	HPV16+ head and neck cancer					2
	Regeneron programs	Undisclosed					3
	Internal	Undisclosed					1
Individualized	VB10.NEO	Melanoma, lung, bladder, renal, head and neck cancer; locally advanced and metastatic tumors					4 <small>A Member of the Roche Group</small>
	VB10.NEO	Locally advanced and metastatic tumors					4 <small>A Member of the Roche Group</small>
Infectious Disease							
	VB10.COV	Pan-variant COVID vaccine					5
	Regeneron programs	Undisclosed					3
	Internal	Undisclosed					1
Autoimmune							
	Internal	Undisclosed					1

1. Wholly-owned by Nykode. Roche supplies atezolizumab; 2. Wholly-owned by Nykode. Merck (MSD) supplies pembrolizumab; 3. Collaboration with Regeneron; 4. Genentech has an exclusive license to VB10.NEO; 5. Collaboration with Adaptive Biotechnologies on SARS-CoV-2 T cell vaccine